8Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs [J]. Mol Cancer Ther, 2002, 1(3) : 205-213.
10Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel resistant phenotype[ J ]. Clin Cancer Res, 1999, 5 ( 11 ) : 3445-3453.
4Perez-Tomas R. Multidrug resistance:retrospect and prospects in anticancer drug treatment [J]. Current Medicinal Chemistry, 2006,13 (16):1859-1876.
5Molnar J, Gyemant N, Tanaka M, et al. Inhibition of multidrug resistance o fcancer cells by natural diterpenes, triterpenes and carotenoids [J]. Curt Pharm Des, 2006, 12(3): 287-311.
6Hait WN, Yang JM. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it [J]. Semin Oncol, 2005, 32(6 Suppl 7): S16-21.
7Tsukuma H, Ajiki W. Descriptive epidemiology of colorectal cancer-intemational comparison [J]. Nippon Rinsho, 2003, 61:25-30.
8Labianca R,Mosconi S,Garassino MC. New strategies in colon cancer adjuvant therapy [J].Annals of Oncology, 2006, 17(7):51-54.
9Scheffer GL, Kool M, Heijn M. Specific detection of multidrug-resistance proteins MRP 1, MRP2, MRP3,MRP5,and MDR3 P-glycoprotein with a panel of monoclonal antibodies [J]. Cancer Res, 2000, 60: 5269-5277.
10Mizutani T, Hattori A. New horizon ofMDR1 (P-glycoprotein) study [J]. Drug Metab Rev, 2005 37(3): 489-510.
